Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain

Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18+
SponsorNRG Oncology

About this trial

This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. FSRS delivers a high dose of radiation to the tumor over 3 treatments. SRS is a type of external radiation therapy that uses special equipment to position the patient and precisely give a single large dose of radiation to a tumor. FSRS may be more effective compared to SRS in treating patients with cancer that has spread to the brain.

Eligibility criteria

Qualifiers

Non-small cell lung cancer

Melanoma

Breast cancer

Renal cell carcinoma

Disqualifiers

None

Trial design

Treatments tested in this trial

  • Computed Tomography
  • Fractionated Stereotactic Radiation Therapy
  • Magnetic Resonance Imaging
  • Stereotactic Radiosurgery

Treatment groups

269 Participants
are divided into 2 treatment groups

Locations

270
Canada
CHUM - Centre Hospitalier de l'Universite de MontrealH2X 3E4, MontrealQuebec, Canada
The Research Institute of the McGill University Health Centre (MUHC)H3H 2R9, MontrealQuebec, Canada
Hong Kong
Pamela Youde Nethersole Eastern Hospital Chai Wan Hong Kong
Ireland
Beacon Hospital18, DublinCo Dublin, Ireland

Sponsors and collaborators

NRG Oncology

Lead sponsor